The arachidonic acid (AA) pathway produces several essential proinflammatory eicosanoids. However, in many neurodegenerative diseases, e.g. Alzheimer’s disease (AD), this pathway is chronically hyperactivated. In brain, primarily monoacylglycerol lipase (MAGL) hydrolyzes the endocannabinoid 2-arachidonoylglycerol to AA, which is further metabolized to generate many proinflammatory eicosanoids. MAGL inhibition, simultaneously reducing the level of eicosanoids and increasing those of neuroprotective endocannabinoids, has proved efficacious in some AD models, reducing neurotoxic β-amyloid (Aβ) levels and improving memory functions. Here, a MAGL inhibitor, JZL184 was chronically administered (16 mg/kg, i.p., 3 x/wk for 5 mo) for 1-1.5 mo and 7-8 mo old transgenic (TG) and wild-type (WT) APP/PS1-21 mice modelling cerebral amyloidosis. According to immunohistochemistry, JZL184 significantly increased the expression levels of cannabinoid receptor 1 in older WT and younger TG and WT mice, decreased cannabinoid receptor 2 and oligomeric Aβ in older and younger TG mice and decreased microglia-specific marker Iba1 in younger TG mice, compared to TG mice treated with vehicle only. However, in the Morris Water Maze test, spatial memory functions improved significantly only in younger TG and WT mice, compared to vehicle-treated littermates. These tentative results suggest that chronic, rather long-term MAGL inhibition can decelerate pathological changes in TG APP/PS1-21 mice but it improves memory functions only when administered at an early stage of the pathology
References
[1]
Schwartz, M. and Deczkowska, A. (2016) Neurological Disease as a Failure of Brain-Immune Crosstalk: The Multiple Faces of Neuroinflammation. Trends Immunol, 37, 668-679. https://doi.org/10.1016/j.it.2016.08.001
[2]
Ransohoff, R.M. (2016) How Neuroinflammation Contributes to Neurodegeneration. Science, 353, 777-783. https://doi.org/10.1126/science.aag2590
[3]
Sastre, M., Walter, J. and Gentleman, S.M. (2008) Interactions between APP Secretases and Inflammatory Mediators. Journal of Neuroinflammation, 5, 25.
https://doi.org/10.1186/1742-2094-5-25
[4]
Heneka, M.T. and O’Banion, M.K. (2007) Inflammatory Processes in Alzheimer’s disease. Journal of Neuroinflammation, 184, 69-91.
https://doi.org/10.1016/j.jneuroim.2006.11.017
[5]
Heneka, M.T., Carson, M.J., El Khoury, J., Landreth, G.E., Brosseron, F., Feinstein, D.L., Jacobs, A.H., Wyss-Coray, T., Vitorica, J., Ransohoff, R.M., Herrup, K., Frautschy, S.A., Finsen, B., Brown, G.C., Verkhratsky, A., Yamanaka, K., Koistinaho, J., Latz, E., Halle, A., Petzold, G.C., Town, T., Morgan, D., Shinohara, M.L., Perry, V.H., Holmes, C., Bazan, N.G., Brooks, D.J., Hunot, S., Joseph, B., Deigendesch, N., Garaschuk, O., Boddeke, E., Dinarello, C.A., Breitner, J.C., Cole, G.M., Golenbock, D.T. and Kummer, M.P. (2015) Neuroinflammation in Alzheimer’s Disease. The Lancet Neurology, 14, 388-405.
https://doi.org/10.1016/S1474-4422(15)70016-5
[6]
Wyss-Coray, T. and Rogers, J. (2012) Inflammation in Alzheimer Disease—A Brief Review of the Basic Science and Clinical Literature. Cold Spring Harbor Perspectives in Medicine, 2, a006346. https://doi.org/10.1101/cshperspect.a006346
[7]
Selkoe, D.J. and Hardy, J. (2016) The Amyloid Hypothesis of Alzheimer’s Disease at 25 Years. EMBO Molecular Medicine, 8, 595-608.
https://doi.org/10.15252/emmm.201606210
[8]
Di Marzo, V. and Petrosino S. (2007) Endocannabinoids and the Regulation of Their Levels in Health and Disease. Current Opinion in Lipidology, 18, 129-140.
https://doi.org/10.1097/MOL.0b013e32803dbdec
[9]
Ashton, J.C. and Glass, M. (2007) The Cannabinoid CB2 Receptor as a Target for Inflammation-Dependent Neurodegeneration. Current Neuropharmacology, 5, 73-80. https://doi.org/10.2174/157015907780866884
[10]
Miller, A.M. and Stella, N. (2008) CB2 Receptor-Mediated Migration of Immune Cells: It Can Go Either Way. British Journal of Pharmacology, 153, 299-308.
https://doi.org/10.1038/sj.bjp.0707523
[11]
Chen, X., Zhang, J. and Chen, C. (2011) Endocannabinoid 2-Arachidonoylglycerol Protects Neurons against β-Amyloid Insults. Neuroscience, 178, 159-168.
https://doi.org/10.1016/j.neuroscience.2011.01.024
[12]
Martín-Moreno, A.M., Reigada, D., Ramírez, B.G., Mechoulam, R., Innamorato, N., Cuadrado, A. and de Ceballos, M.L. (2011) Cannabidiol and Other Cannabinoids Reduce Microglial Activation in Vitro and in Vivo: Relevance to Alzheimer’s Disease. Molecular Pharmacology, 79, 964-973.
https://doi.org/10.1124/mol.111.071290
[13]
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N.E., Schatz, A.R., Gopher, A., Almog, S., Martin, B.R., Compton, D.R., et al. (1995) Identification of an Endogenous 2-Monoglyceride, Present in Canine Gut, That Binds to Cannabinoid Receptors. Biochemical Pharmacology, 50, 83-90.
https://doi.org/10.1016/0006-2952(95)00109-D
[14]
Blankman, J.L., Simon, G.M. and Cravatt, B.F. (2007) A Comprehensive Profile of Brain Enzymes that Hydrolyze the Endocannabinoid 2-Arachidonoylglycerol. Chemistry & Biology, 14, 1347-1356. https://doi.org/10.1016/j.chembiol.2007.11.006
Chen, R., Zhang, J., Wu, Y., Wang, D., Feng, G., Tang, Y.P., Teng, Z. and Chen C. (2012) Monoacylglycerol Lipase Is a Therapeutic Target for Alzheimer’s Disease. Cell Reports, 2, 1329-1339. https://doi.org/10.1016/j.celrep.2012.09.030
[17]
Pihlaja, R., Takkinen, J., Eskola, O., Vasara, J., López-Picón, F.R., Haaparanta-Solin, M. and Rinne J.O. (2015) Monoacylglycerol Lipase Inhibitor JZL184 Reduces Neuroinflammatory Response in APdE9 Mice and in Adult Mouse Glial Cells. Journal of Neuroinflammation, 12, 81. https://doi.org/10.1186/s12974-015-0305-9
[18]
Piro, J.R., Benjamin, D.I., Duerr, J.M., Pi, Y., Gonzales, C., Wood, K.M., Schwartz, J.W., Nomura, D.K. and Samad, T.A. (2012) A Dysregulated Endocannabinoid-Eicosanoid Network Supports Pathogenesis in a Mouse Model of Alzheimer’s Disease. Cell Reports, 1, 617-623.
https://doi.org/10.1016/j.celrep.2012.05.001
[19]
Grabner, G.F., Eichmann, T.O., Wagner, B., Gao, Y., Farzi, A., Taschler, U., Radner, F.P., Schweiger, M., Lass, A., Holzer, P., Zinser, E., Tschop, M.H., Yi, C.X. and Zimmermann, R. (2016) Deletion of Monoglyceride Lipase in Astrocytes Attenuates Lipopolysaccharide-Induced Neuroinflammation. Journal of Biological Chemistry, 291, 913-923. https://doi.org/10.1074/jbc.M115.683615
[20]
Radde, R., Bolmont, T., Kaeser, S.A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M.E., Jaggi, F., Wolburg, H., Gengler, S., Haass, C., Ghetti, B., Czech, C., Holscher, C., Mathews, P.M. and Jucker, M. (2006) Aβ42-Driven Cerebral Amyloidosis in Transgenic Mice Reveals Early and Robust Pathology. EMBO Reports, 7, 940-946. https://doi.org/10.1038/sj.embor.7400784
[21]
Long, J.Z., Nomura, D.K. and Cravatt, B.F. (2009) Characterization of Monoacylglycerol Lipase Inhibition Reveals Differences in Central and Peripheral Endocannabinoid Metabolism. Chemistry & Biology, 16, 744-753.
https://doi.org/10.1016/j.chembiol.2009.05.009
[22]
Morris, R. (1984) Developments of a Water-Maze Procedure for Studying Spatial Learning in the Rat. Journal of Neuroscience Methods, 11, 47-60.
https://doi.org/10.1016/0165-0270(84)90007-4
[23]
Tanila, H. (2012) Wading Pools, Fading Memorie—Place Navigation in Transgenic Mouse Models of Alzheimer’s Disease. Frontiers in Aging Neuroscience, 4, 11.
https://doi.org/10.3389/fnagi.2012.00011
[24]
Aso, E. and Ferrer, I. (2016) CB2 Cannabinoid Receptor as Potential Target against Alzheimer’s Disease. Frontiers in Neuroscience, 10, 243.
https://doi.org/10.3389/fnins.2016.00243
